Resolved and unresolved issues in the prevention and treatment of coronary artery disease: A workshop consensus statement

American Heart Journal

Volumn 121, Issue 4 PART 1, 1991, Pages 1244-1263

  Dzau, Victor ^a   Braunwald, Eugene ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; REVIEW;

CORONARY DISEASE; CORONARY THROMBOSIS; DIABETES MELLITUS; HUMAN; HYPERTENSION; MYOCARDIAL INFARCTION; RISK FACTORS; SUPPORT, NON-U.S. GOV'T;

EID: 0026061942     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/0002-8703(91)90694-D     Document Type: Article

References (124)

1. Lowering plasma cholesterol levels decreases risk of coronary heart disease: an overview of clinical trials
2. The Lipid Research Clinics Coronary Primary Prevention Trial results I Reduction in incidence of coronary heart disease
3. The Lipid Research Clinics Coronary Primary Prevention Trial results II The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
4. Niacin or lovastatin, combined with colestipol, regress coronary atherosclerosis and prevent clinical events in men with elevated apolipoprotein B [Abstract]
5. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study
6. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts
7. Report of the National Cholesterol Education Program Expert Panel on detection evaluation and treatment of high blood cholesterol in adults
8. Relative impact of targeted versus population-wide cholesterol interventions on the incidence of coronary heart disease. Projections of the Coronary Heart Disease Policy Model
9. The place of HDL in clinical management. A perspective from the National Cholesterol Education Program
10. Multiple risk functions for predicting coronary heart disease: the concept, accuracy, and application
11. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity
12. 5α-Cholest-8(14)-en-3β-ol-15-one lowers serum cholesterol and induces profound changes in the levels of lipoprotein cholesterol and apoproteins in monkeys fed a diet of moderate cholesterol content
13. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit
14. Serum cholesterol, blood pressure and mortality: implications from a cohort of 361,662 men
15. Epidemiology of coronary heart disease: the Framingham Study
16. Diet, serum cholesterol and death from coronary heart disease: the Western Electric Study
17. Treatment of hypertension and its effect on cardiovascular risk factors: data from the Framingham Heart Study
18. Antihypertensive treatment and plasma lipoprotein levels: the associations in data from a population study
19. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension
20. Elevation of serum lipid levels during diuretic therapy of hypertension
21. Effects of treatment on morbidity in hypertension results in patients with diastolic blood pressure averaging 90 through 114 mm Hg
22. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials
23. Baseline rest electrocardiographic abnormalities antihypertensive treatment and mortality in the multiple Risk Factor Intervention Trial
24. The effect of antihypertensive drug treatment on mortality in the presence of resting electrocardiographic abnormalities at baseline The HDFP experience
25. 1984 Report
26. The incidence of treated and stage renal disease in the eastern United States
27. Renal parenchymal involvement in essential hypertension
28. Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus
29. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes
30. Hypertension and renal diseases
31. Therapeutic implications of converting-enzyme inhibitors in renal disease
32. Platelet-derived growth factor synthesis in mesangial cells: induction by multiple peptide mitogens
33. The calcium antagonist nifedipine inhibits arterial smooth muscle cell proliferation
34. N-desulfated/acetylated heparin ameliorates the progression of renal disease in rats with subtotal renal ablation
35. Heparin and glomerular epithelial cell-secreted heparin-like species inhibit mesangial cell proliferation
36. Disparities in incidence of diabetic end stage renal disease according to race and type of diabetes
37. Racial differences in the incidence of treatment for end stage renal disease
38. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension
39. Endothelium-dependent vascular responses: mediators and mechanisms
40. Coronary heart disease and urinary albumin excretion rate in type 2 (non-insulin-dependent) diabetic patients
41. Is insulin the link between hypertension and obesity?
42. The effect of insulin on renal sodium metabolism
43. Insulin and hypertension: lessons from obesity
44. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance
45. Effects of long-term antihypertensive treatment on kidney function in diabetic nephropathy
46. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy
47. Cardiac hypertrophy: useful adaptation or pathologic process?
48. Cardiac renin-angiotensin system molecular and functional aspects
49. Alpha-1 adrenergic receptor stimulation of sarcomeric actin isogene transcription in hypertrophy of cultured rat heart muscle
50. Echocardiographic left ventricular hypertrophy in the general population is associated with increased two-year mortality, independent of the standard coronary risk factors
51. Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Study
52. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men
53. Usefulness of echocardiographic left ventricular hypertrophy in predicting new coronary events and atherothrombotic brain infarction in patients over 62 years of age
54. Reversal of left ventricular hypertrophy in hypertensive patients treated with methyldopa
55. Vasodilators and regression of left ventricular hypertrophy: hydralazine versus prazosin in hypertensive humans
56. Cardiovascular effects and regional blood flow distribution associated with angiotensin converting enzyme inhibition (captopril) in essential hypertension
57. Cardiac hypertrophy in hypertension
58. Echocardiographic studies of regression of left ventricular hypertrophy in hypertension
59. Long-term minoxidil therapy and renal function, cardiac function, hypertrichosis and blood pressure
60. Combined effects of hypertension and chronic running program on rat heart
61. Collagen in the hypertrophied, pressure-overloaded myocardium
62. The structure of the resistance vasculature in essential hypertension
63. Cell biology of vascular hypertrophy in systemic hypertension
64. Prognostic importance of myocardial ischemia detected by ambulatory monitoring in patients with stable coronary artery disease
65. Silent ischemia as a marker for early unfavorable outcomes in patients with unstable angina
66. Insights into the pathogenesis of acute ischemic syndromes
67. Atherosclerosis impairs flow-mediated dilatation of coronary arteries in humans
68. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries
69. Pathological view of sudden death
70. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis: characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi
71. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits
72. Regression of atherosclerotic lesions by high density lipoprotein plasma fractions in the cholesterol-fed rabbit
73. Thrombosis and the development of atherosclerosis: Rokitansky revisited
74. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications
75. Antiplatelet therapy in coronary disease progression: reduced infarction and new lesion formation
76. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
77. Randomized trial of intravenous streptokinase oral aspirin both or neither among 17187 cases of suspected acute myocardial infarction
78. Immediate versus delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction TIMI IIA results
79. Tissue plasminogen activator (t-PA)
80. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator
81. Potential use of thrombolytic therapy before hospitalization
82. The stunned myocardium: prolonged, post-ischemic ventricular dysfunction
83. Bolli R. Oxygen-derived free radicals and postischemic myocardial dysfunction (“stunned” myocardium). J Am Coll Cardiol 12: 239-249.
84. Pathophysiology and pathogenesis of stunned myocardium. Depressed Ca2+ activation of contraction as a consequence of reperfusion-induced cellular calcium overload in ferret hearts
85. Nifedipine administered post-reperfusion ablates systolic contractile dysfunction of postischemic “stunned” myocardium
86. Acidosis during early reperfusion prevents myocardial stunning in perfused ferret hearts
87. Granulocytes cause reperfusion ventricular dysfunction after 15 minutes of ischemia in the dog
88. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor
89. Hormonal and cardiac effects of converting enzyme inhibition in rat myocardial infarction
90. Protective effects of captopril against ischemia/reperfusion induced ventricular arrhythmias in vitro and in vivo
91. Functional infarct expansion, left ventricular dilation and iso-volumic relaxation time following coronary occlusion: a two-dimensional echocardiographic study
92. Effects of converting enzyme inhibitors: ramipril and enalapril on peptide action and sympathetic neurotransmission in the isolated heart
93. Neuroendocrine changes in acute myocardial infarction
94. Preservation of ischemic myocardium by a new converting enzyme inhibitor, enalaprilic acid, in acute myocardial infarction
95. Does captopril attenuate reperfusion-induced myocardial dysfunction by scavenging free radicals?
96. Cardiac arrhythmias—a new indication for angiotensin-converting enzyme inhibitors?
97. Myocardial infarct expansion, infarct extension and reinfarction: pathophysiologic concepts
98. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction
99. Ventricular remodeling following myocardial infarction: experimental observations and clinical implications
100. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction
101. Infarct artery perfusion and changes in left ventricular volume in the month after acute myocardial infarction
102. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded?
103. Secondary prevention with calcium channel-blocking drugs in patients after myocardial infarction: a critical review
104. The effect of diltiazem on mortality and reinfarction after myocardial infarction
105. Diltiazem and reinfarction in patients with non-Q wave myocardial infarction. Results of a double-blind, randomized multicenter trial
106. Risk stratification and survival after myocardial infarction
107. Preliminary report effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
108. Secondary prevention of vascular disease by prolonged antiplatelet therapy
109. Ventricular enlargement and reduced survival after myocardial infarction
110. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction
111. Pathogenesis of sodium and water retention in high output and low output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy
112. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
113. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics
114. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
115. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study
116. Why patients with heart failure die: hemodynamic and functional determinants of survival
117. Captopril in heart failure. A double-blind controlled trial
118. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure
119. Lack of correlation between exercise capacity and indices of resting left ventricular performance in heart failure
120. New positive inotropic agents in the treatment of congestive heart failure
121. New positive inotropic agents in the treatment of congestive heart failure
122. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure